SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors digest recent earnings results, with the community actively debating the company's ability to drive significant year-over-year revenue growth through its QNX division and the ramp-up of new automotive software partnerships. While some market participants remain cautious regarding historical performance and guidance, others are increasingly focused on the potential for long-term expansion in the software-defined vehicle market.

CRINGE is a Solana meme token centered around all images, videos, and actions which are cringe!  Warning: Cringe Alert! Remember, folks! Just like we don't judge people based on race, ethnicity, or color, we shouldn't judge them for being cringe. After all, cringe isn't ugly - it's just... special. 😉  Embrace your inner cringe, because in a world full of copycats, being cringey is the new cool!  Meme coins are driven by community, and our community is CRINGE as heck!

CRINGE

CRINGE is generating intense community debate as participants navigate extreme price volatility and widespread concerns over potential pump-and-dump activity within the low market cap crypto sector. Investors are actively weighing the allure of rapid gains against the inherent risks of memecoin speculation, leading to polarized discussions regarding the long-term viability of the asset.

On November 2021, 4chan created a female alternative to Wojak/PePe called “GleGle.”

glegle

GLEGLE is trending as retail investors engage in highly speculative, community-driven trading, with many participants actively discussing it as a high-risk "lotto ticket" play while analyzing chart structures for potential expansion. While some members are skeptical, describing the activity as gambling or a "pump and dump," others are focused on building momentum for the token by encouraging social media promotion and community holding efforts.

cowgorithm

The community is actively discussing Cowgorithm as a high-risk speculative opportunity, focusing on its current price consolidation and perceived strength relative to other assets in the meme coin sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive clinical data update and a significant analyst price target increase, fueling intense community discussion regarding its potential as a best-in-class treatment. Investors are actively monitoring institutional accumulation patterns and ongoing M&A speculation, with many focused on upcoming trial readouts that serve as key catalysts for potential long-term value.

NKN is building the largest blockchain for network sharing.

New Kind of Network

NKN is currently experiencing high volatility driven by speculative retail interest, social media buzz surrounding potential short squeezes, and rumors of partnership developments. Community members are actively debating the token's long-term utility in decentralized infrastructure versus its history of rapid price pumps and sharp corrections.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is facing heightened investor scrutiny as the stock experiences volatility amid mixed earnings results, with the community actively debating whether the recent performance represents a deep-value opportunity or a sustained downtrend. Traders are closely monitoring the company's ability to capitalize on AI infrastructure demand and potential hyperscaler partnerships, while some express frustration over leadership and recent guidance.

iShares Trust - iShares iBoxx USD Investment Grade Corporate Bond ETF

iShares iBoxx USD Investment Grade Corporate Bond ETF

The iShares iBoxx USD Investment Grade Corporate Bond ETF (LQD) is under intense scrutiny as investors weigh its role as a liquidity gauge against widening credit spreads and persistent duration risk. Community sentiment remains cautious, with active debates centered on whether current price levels represent a historical buying opportunity or a signal of deeper credit market stress as high-grade corporate bonds increasingly correlate with broader equity market volatility.

Select Sector SPDR Trust (The) - State Street Real Estate Select Sector SPDR ETF

Real Estate Select Sector SPDR Fund

The Real Estate Select Sector SPDR Fund (XLRE) is currently trending as investors weigh the impact of shifting interest rate expectations and persistent inflation concerns on the housing market. Community discussion is focused on the sector's volatility, with traders actively debating whether recent price action represents a consolidation phase or a sign of broader structural weakness in commercial and residential real estate.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

Incyte is currently trending as investors focus on a critical transition period, balancing strong legacy revenue from Jakafi against the pressure to demonstrate pipeline success through upcoming trial readouts and clinical milestones. The community is actively debating the company's valuation as a potential acquisition target, weighing its cash position and strategic partnerships against the looming patent cliffs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Cathie Wood’s ARK Investment Management bought more Tempus shares this week, even as the stock hit a one-year low and the firm trimmed exposure across several large tech holdings.</li><li>So far this year, ARKK and ARKG have poured nearly $28 million into Tempus shares.</li><li>The buying followed expanding AI-driven oncology partnerships with Daiichi Sankyo, Merck, Blood Cancer United, NYU Langone Health and Northwestern Medicine.</li></ul>Shares of Tempus AI Inc. (TEM) drew renewed attention this week after Cathie Wood’s ARK Investment Management added to its position while cutting stakes across several large tech firms, signaling continued conviction even as the stock hit a one-year low.<a href="https://stocktwits.com/symbol/TEM">TEM stock</a> fell nearly 3% on Thursday and is headed for its fifth straight weekly loss, shedding roughly 25% over the past five weeks.<h2 class="st-heading-2">Tempus Only Stock ARKK Bought In Latest Buy</h2>On Thursday, ARK Investment Management purchased 51,881 shares through the ARK Innovation ETF (ARKK), worth $2.4 million based on Tempus’ closing price of $45.53. Notably, Tempus was the only stock ARKK bought in the session, even as the firm reduced exposure across several large tech holdings, including Alphabet, Baidu, Broadcom, Illumina, Archer Aviation, AMD, Nvidia and Meta.The purchase followed additional accumulation a day earlier, when ARKK acquired 72,290 shares and the ARK Genomic Revolution ETF (ARKG) added 12,649 shares, worth $4 million.Earlier in the quarter, ARK accumulated shares following Tempus’ earnings report and momentum from its partnerships. On Feb.25, ARKK bought 179,013 shares, while ARKG added 33,812 shares, implying purchases worth about $11.4 million.The accumulation this year began on Feb.12, when ARKK purchased 174,585 shares and ARKG added 35,716 shares, representing roughly $10.7 million using Tempus’ $50.78 closing price. Cumulatively, ARK poured nearly $28 million into Tempus shares so far this year.<h2 class="st-heading-2">Tempus Expands Big Pharma AI Deals</h2>ARK’s accumulation comes after Tempus expanded its role in precision oncology research and clinical-trial optimization pipelines. Most recently, Tempus partnered with Japanese pharma giant Daiichi Sankyo to develop a new cancer therapy, using its Prism2 AI model to better identify patients most likely to benefit from treatment.Earlier this month, the company expanded its collaboration with Merck to support biomarker discovery across oncology and potentially broader therapeutic programs using its Lens platform and real-world datasets. Tempus also announced a deal with Blood Cancer United to build a registry focused on pediatric acute myeloid leukemia (AML).The developments followed additional collaborations this year with Median Technologies, NYU Langone Health and Northwestern Medicine supporting genomic testing workflows, lung-cancer screening and molecular oncology programs.<h2 class="st-heading-2">Wall Street Sees Long-Term Upside For Tempus</h2>Wall Street commentary this year reflected some price-target resets following quarterly results, but maintained confidence in Tempus’ long-term platform strategy. H.C. Wainwright raised its target to $95 and maintained a 'Buy' rating, while Baird lifted its target to $68 and reiterated an 'Outperform' rating. BTIG also maintained a 'Buy' rating, citing Tempus’s “first mover advantage on its large data business” and $1.1 billion backlog supporting expansion.Meanwhile, JPMorgan lowered its price target to $60 and kept a 'Neutral' rating, citing “clouded visibility” around data-segment upside, while TD Cowen cut its target to $70 and maintained a 'Hold' rating. Mizuho initiated coverage with an 'Outperform' rating and a $100 target, calling precision oncology diagnostics a $40 billion market growing about 30% annually.Tempus reported fourth-quarter revenue of $367.2 million, beating estimates, and projected fiscal-year 2026 revenue of about $1.59 billion, roughly in line with forecasts. CEO Eric Lefkofsky said that growth in diagnostics volumes and the company’s AI-driven data platform is expected to support expansion in the coming years.<h2 class="st-heading-2">What Do Retail Traders Feel About Tempus AI?</h2>On Stocktwits, retail sentiment for TEM has been in the ‘bearish’ territory over the past week, slipping from ‘extremely bullish’ levels a month ago amid over a 90% surge in message volumes this quarter. Meanwhile, the stock has seen nearly a 50% jump in watchers over the past year.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/tem_ss_png_ca8662c8d0.webp" alt="tem ss.png" width="978" height="143"><figcaption>TSLA sentiment and message volume as of March 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/GoAt2OG/message/648701463">expressed</a> optimism, noting that “The only thing Cathie bought today was us here at Tempus.”<stembedurl>https://stocktwits.com/GoAt2OG/message/648701463</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/MihaiGG/message/648612357">said</a>, “Experience told me that this is a good moment to buy, with what we can or what we have. Cathie is loading up, so, [why] don’t we? It will boom, someday, but success needs pain.”<stembedurl>https://stocktwits.com/MihaiGG/message/648612357</stembedurl>TEM stock has declined 15% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-misses-gas-price-tailwind-ahead-of-q1-delivery-report/cZ3uFS9RIli">Tesla Stock Fails To Catch Tailwind From Surging Gas Prices Ahead Of Crucial Q1 Delivery Report</a>

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Tempus AI Stock Near 1-Year Low: Cathie Wood’s ARK Buys More While Offloading Nvidia, Meta, Other Tech Plays

Tempus AI was the only stock purchased by ARK Innovation ETF (ARKK) in the latest session, signaling targeted conviction.

Equity

<ul class="summary-bullets"><li>CRISPR Therapeutics said the debt securities will rank as senior unsecured obligations.</li><li>Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.</li><li>In January, the company said it had around $2 billion in cash, cash equivalents, and marketable securities.</li></ul>CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts.&nbsp;The company said it intends to issue $350 million in convertible senior notes, scheduled to mature in 2031, subject to prevailing market conditions and investor demand.<h2 class="st-heading-2">Structure Of The Convertible Notes</h2>According to the company, the debt securities will rank as senior unsecured obligations.&nbsp;Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.&nbsp;Unless the notes are converted into shares, repurchased, or redeemed earlier, they will come due on Mar. 1, 2031. If investors choose to convert the notes, CRISPR will settle the conversion by issuing common shares with a nominal value of CHF 0.03 ($0.039) each.CRISPR Therapeutics said it expects to allocate the net proceeds from the sale for broad corporate needs.&nbsp;<a href="https://stocktwits.com/symbol/CRSP">CRISPR Therapeutics stock</a> traded over 6% lower in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">2026 Goals</h2>CRISPR Therapeutics is developing a wide range of programs in blood disorders, cancer, regenerative medicine, heart and autoimmune diseases, and other rare conditions. CASGEVY is the first CRISPR-based therapy for patients with sickle cell disease and transfusion-dependent beta thalassemia.In January, it&nbsp;outlined its strategic priorities for 2026, highlighting multiple expected milestones across its gene-editing and siRNA portfolios. It also emphasized a strong financial position, with around $2 billion in cash, cash equivalents, and marketable securities to support ongoing research and commercial activities.CRSP stock has gained over 23% in the last 12 months.&nbsp;Exchange Rate: 1CHF=1.29USDAlso See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-surged-today-what-is-fueling-the-rally/cZdovHXRI7O">CAPR Stock Surged 17% Today — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Crispr Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Is CRSP Stock Falling Pre-Market Today?

CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts. 

Why Is CRSP (CRISPR Therapeutics) Stock Falling Pre-Market Today?

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.


<ul class="summary-bullets"><li>The company touted milestones achieved across multiple programs, including the first AI-enabled proof-of-concept in Familial Adenomatous Polyposis with its drug candidate, REC-4881.</li><li>Recursion stated that it has entered 2026 with five differentiated clinical programs advancing with defined next-stage milestones.</li><li>The company added that its cash runway now extends into early 2028, based on its current operating plans and without additional financing.</li></ul>Recursion Pharmaceuticals Inc. (RXRX) shares soared 16% in Wednesday’s pre-market trade after the company’s fourth-quarter (Q4) results beat Wall Street expectations.Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.“Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value,” said Najat Khan, CEO &amp; President of Recursion.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/RXRX">Recursion Pharmaceuticals</a> trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">Recursion Touts Milestones</h2>The company touted milestones across multiple programs, including the first AI-enabled proof-of-concept in Familial Adenomatous Polyposis (FAP) with its drug candidate, REC-4881, and the achievement of the fifth program milestone with Sanofi.Recursion stated that this highlights the increasing maturity of its model that integrates biology, chemistry, and clinical development into a continuous learning system.“We enter 2026 with five differentiated clinical programs advancing with defined next-stage milestones, a growing discovery portfolio informed by proprietary platform insights, and more than $500 million in upfront and progress-based milestone payments earned to date,” Khan added.<h2 class="st-heading-2">Recursion Says Cash Runway Extends Into Early 2028</h2>The company added that its cash runway now extends into early 2028, based on its current operating plans and without additional financing.Its cash, cash equivalents, and restricted cash were $753.9 million as of Dec. 31, 2025, compared to $603 million as of Dec. 31, 2024.<a href="https://stocktwits.com/symbol/RXRX">RXRX stock</a> is down 14% year-to-date and 61% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sgml-alb-lac-stocks-rise-zimbabwe-suspends-exports-of-lithium-concentrates/cZRyTrXR46v">SGML, ALB, LAC Stocks Rise As Zimbabwe Suspends Exports Of Lithium Concentrates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Recursion is an American biotechnology company that combines machine learning, automation, and experimental biology. (Photo illustration by Cheng Xin/Getty Images)

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

<ul class="summary-bullets"><li>The company said that its COMP360 drug is the first classic psychedelic to consistently achieve a highly statistically significant result and a clinically meaningful effect.</li><li>Compass said that across both Phase 3 trials to date, COMP360 has demonstrated a generally well-tolerated and safe profile, with no unexpected safety findings.</li><li>The company added that a clinically meaningful reduction in MADRS of more than 25% was observed in a significant number of participants receiving the 25 mg dose in both COMP005 and COMP006 trials.</li></ul>Compass Pathways PLC (CMPS) shares were up more than 23% in Tuesday’s pre-market trade after the company announced that it had successfully achieved the primary endpoint in a Phase 3 clinical trial.Compass announced on Tuesday that its two Phase 3 trials have confirmed a highly differentiated profile for COMP360 for treatment-resistant depression (TRD).<h2 class="st-heading-2">Here Are Compass’ Findings</h2>The company said that its COMP360 drug is the first classic psychedelic to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profile.COMP360, a synthetic and proprietary formulation of psilocybin, is designed for TRD. Compass said that across both Phase 3 trials to date, COMP360 has demonstrated a generally well-tolerated and safe profile, with no unexpected safety findings.The company reported that in COMP006, two doses of COMP360 with a dose of 25 mg versus a dose of 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by the Montgomery-Asberg Depression Rating Scale (MADRS.)MADRS is a 10-item clinician-administered tool used to measure the severity of depressive episodes, ranging from 0 to 60. Compass said that the difference in the MADRS score between the 25 mg dose and the 1 mg dose was -3.8.The company added that a clinically meaningful reduction in MADRS of more than 25% was observed in a significant number of participants receiving the 25 mg dose in both COMP005 and COMP006 trials. Compass said that COMP005 participants witnessed a 25% reduction in MADRS, while the reduction stood at 39% among COMP006 participants.The company said that it has sought a meeting with the U.S. Food and Drug Administration (FDA) to discuss a rolling submission and review. It expects to complete a New Drug Application (NDA) submission in the fourth quarter (Q4).“These data strengthen our conviction in the highly differentiated profile for COMP360 and given the urgent need for new treatments in TRD, we are advancing our discussions with the FDA, with the goal of submitting an NDA in Q4 and securing approval,” said Compass CEO Kabir Nath.The company announced in January that the U.S. Food and Drug Administration (FDA) had accepted its Investigational New Drug (IND) application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), allowing the company to begin a late-stage trial.Compass said it is working on making COMP360 ready for commercial launch by the end of the year for TRD as well.<h2 class="st-heading-2">What Does Compass Do?</h2>London-headquartered Compass is a biotechnology company engaged in the development of solutions for mental health conditions through its investigational COMP360 synthetic psilocybin treatment.The company expects to release the 26-week Part B data from its COMP006 trial for TRD in the early third quarter (Q3) this year.<h2 class="st-heading-2">Here’s What Stocktwits Users Think</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CMPS">Compass</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels. The CMPS stock was the second most trending ticker on the platform at the time of writing.One bullish user called the trial results great, while adding that an FDA approval is “likely.”<stembedurl>https://stocktwits.com/Rocketzz/message/645094778</stembedurl>Another user called the results huge news, while saying, “just imagine what different dosing regimens could reveal with this safety profile.”<stembedurl>https://stocktwits.com/VikaDelic/message/645094710</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down 14% year-to-date, but up 27% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/goldman-sachs-david-solomon-warns-of-shocks-if-deficit-not-controlled/cZR5xtUR4t5">Goldman Sachs CEO David Solomon Warns Of 'Shocks' If Deficit Is Not Brought Under Control And Growth Rate Is Not Brought Up: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

<ul class="summary-bullets"><li>For the full fiscal year 2026, the company now expects total revenue in the range of $435 million to $440 million, compared to prior guidance of $425 to $435 million.</li><li>For the current quarter (Q2), the company expects to report revenue of approximately $107 million to $108 million, marking a growth of approximately 16% percent year over year.</li><li>Twist also said that it expects to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.</li></ul>Shares of Twist Bioscience Corporation (TWST) jumped 8% on Monday after the company hiked its fiscal year 2026 revenue guidance on the heels of a first-quarter (Q1) earnings report that beat Wall Street estimates.<h2 class="st-heading-2">Upbeat Outlook</h2>For the full fiscal year 2026, the company now expects total revenue in the range of $435 million to $440 million, compared to prior guidance of $425 to $435 million, and exceeding an analyst estimate of $430.84 million, according to data from Fiscal AI. &nbsp;For the current quarter (Q2), the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.twistbioscience.com/static-files/af6dbd56-d91e-429e-b337-a8e2675fc255">expects</a> to report revenue of approximately $107 million to $108 million, marking a growth of about 16% percent year over year at the midpoint, and exceeding an estimated $105.08 million.Twist also said that it expects to achieve adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) breakeven in the fourth-quarter of fiscal 2026.<h2 class="st-heading-2">Q1 Numbers</h2>For Q1, the company reported total revenue of $103.7 million, marking a growth of 17%, and above an expected $100.33 million, due to an increase in customers. The company said that it shipped products to about 2,538 customers in Q1 of fiscal 2026, versus approximately 2,376 in the same quarter of the previous fiscal year.Net loss for the quarter came in at $30.5 million, compared to $31.6 million in the corresponding quarter of fiscal 2025.The company also ended the quarter with $198 million in cash, cash equivalents, and short-term investments.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TWST stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A user applauded the earnings as “solid” progress for investors.<stembedurl>https://www.stocktwits.com/DBRGLong/message/643661292</stembedurl><a href="https://stocktwits.com/symbol/TWST">TWST stock</a> has dropped 16% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/oracle-bond-offering-funding-ai-cloud-infrastructure/cZbgYA1R4ki">ORCL Stock In Focus As Tech Giant Reportedly Launches Bond Offering To Cover Half Of 2026 Funding Needs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TWST Shares Rise 8% — What’s Driving The Rally?

Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates. 

Cathie Wood, Founder & CEO, Ark Invest, speaks during the second day of the FII PRIORITY Summit

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD

ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October.

<ul class="summary-bullets"><li>The company expects to submit a biologics license application for risto-cel by year-end 2026.</li><li>Beam ended 2025 with an estimated $1.25 billion in cash, extending its operating runway into 2029.</li><li>Management will further discuss the developments at the J.P. Morgan Healthcare Conference on January 13.</li></ul>Beam Therapeutics Inc. (BEAM) received a boost from William Blair, which reacted&nbsp;positively to the company’s update on its alignment with the U.S. FDA, citing improved visibility into the data required for regulatory submissions. The firm pointed to progress in Beam’s sickle cell therapy risto-cel and its liver-targeted program BEAM-302.William Blair also noted that both programs’ acceptance into the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot program could speed development and regulatory review. The brokerage firm reiterated its ‘Outperform’ rating.<h2 class="st-heading-2">Updates on BEAM-302 and Risto-cel</h2>Beam’s update outlined progress across its genetic disease and hematology franchises. The company said it has aligned with the FDA on a potential accelerated approval pathway for BEAM-302 in alpha-1 antitrypsin deficiency (AATD), based on biomarker endpoints. BEAM-302 has shown an in vivo correction of a disease-causing mutation in AATD, and Beam Therapeutics plans to expand patient enrollment to support a future biologics license application (BLA).<a href="https://stocktwits.com/symbol/BEAM">Beam Therapeutics’ stock</a> gained over 28% On Monday afternoon.In hematology, Beam expects to submit a BLA for risto-cel by year-end 2026. The BEACON Phase 1/2 trial is fully enrolled, manufacturing is complete, and recent data continue to show strong efficacy and a predictable manufacturing profile, potentially improving patient experience and treatment center capacity, the company said.Beyond its clinical progress, Beam ended 2025 with an estimated $1.25 billion in cash, extending its operating runway into 2029. This positions the company to fund the anticipated launch of risto-cel and execute pivotal development plans for BEAM-302 without near-term financing risk.Management will further discuss these developments at the J.P. Morgan Healthcare Conference on January 13.<h2 class="st-heading-2">Retail Remains Extremely Bullish</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/BEAM_jpg_e1fba90ff6.webp" alt="BEAM.jpg" width="925" height="99"><figcaption>&nbsp;</figcaption></figure>One user expects a buyout.<stembedurl>https://stocktwits.com/ReadyMate/message/641529269</stembedurl>Another user expects ‘good times’ ahead.<stembedurl>https://stocktwits.com/Millard_Findlemeyer/message/641539254</stembedurl>Over the past year, the stock has gained around 38%.Read also:<a href="https://stocktwits.com/news-articles/markets/equity/why-did-planet-labs-stock-gain-today/cmUad7cR4Ej">&nbsp;Planet Labs Stock Gained 7% Today — What Is The Swedish Military Deal About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise 

William Blair welcomed the company’s update on its alignment with the U.S. FDA, saying it gives clear visibility into the data needed for regulatory filings.

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Cathie Wood Loves This Under-the-Radar AI Stock. Is It Time for You to Buy Now?

The popular investor poured $366.2 million in the company’s shares to carry out her latest purchase.

Shares of Tempus AI, Inc. were volatile Tuesday, surging to highs last seen in mid-November before paring gains to trade slightly higher.Trading volume was nearly double the daily average as the healthcare tech firm confirmed it will report fourth-quarter and full-year 2024 earnings on Feb. 24, with a conference call at 4:30 p.m. ET.Wall Street expects the company to report an adjusted loss of $0.16 per share on revenue of $203.12 million.Retail sentiment on Stocktwits remained ‘bullish,’ though the score read slightly lower than last week following insider selling.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TEM_sentiment_and_message_volume_Feb_11_564e2ba31d.png" alt="TEM sentiment and message volume Feb 11.png" width="1318" height="324"><figcaption>TEM sentiment and message volume Feb 11 as of 11:45 am ET | source: Stocktwits</figcaption></figure>CEO and Chairman Eric Lefkofsky recently sold nearly 240,000 shares between Feb. 5-7, netting over $16.2 million, while CFO Jim Rogers sold 8,712 shares for $588,669, as per SEC filings.Stocktwits users had mixed reactions. One trader noted the stock “gave back most of the pump,” suggesting weak holding interest amid short pressure.&nbsp;Another pointed to a bullish technical setup, predicting a move toward $80.<stembedurl>https://stocktwits.com/phijammaslamma/message/603757859</stembedurl><stembedurl>https://stocktwits.com/CoBear/message/603746559</stembedurl>Tempus AI has gained a lot of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tem-stock-heads-for-best-rally-in-5-months/chb9WlYR8z">attention</a> since launching an AI-enabled personal health app last month.But it also made headlines after former House Speaker Nancy Pelosi purchased 50 call options in the stock, a trade closely watched by retail investors.Last week, the company announced the completion of its $600 million acquisition of Ambry Genetics.&nbsp;TD Cowen reportedly believes the acquisition strengthens Tempus with a $300-million profitable lab, enhances product offerings, and accelerates its path to positive free cash flow.The research firm, however, thinks Ambry’s slower growth is a concern.Tempus AI stock has surged over 70% since its June 2024 IPO, with its Stocktwits following up nearly 700% in three months.&nbsp;Short interest has also climbed from 3.9% at the start of 2025 to 7.3% by the end of January, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. 

Tempus AI Stock Swings Wildly As Earnings Near, Retail’s Cautiously Optimistic After Insider Sales 

The company has gained a lot of attention since launching an AI-enabled personal health app last month.

ARK ETF Trust - ARK Genomic Revolution ETF

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

ARKG
ARK Investment Management LLC - ARK Genomic Revolution ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ARKG News

ARKGARK Investment Management LLC - ARK Genomic Revolution ETF